中國創意控股(08368.HK):完成向樑龍飛配發3600萬股代價股份
格隆匯3月29日丨中國創意控股(08368.HK)公佈,有關與真相影業就發行電影進行合作,已於2022年3月29日達致完成。完成後,公司以發行價1.00港元向合作伙伴的代名人樑龍飛先生(為合作伙伴的創辦人及合作協議的擔保人,"代名人")配發及發行合共3600萬股代價股份。
據悉,真相影業是一家於香港成立的有限公司,在中國內地和港台地區從事電影和電視節目的發行、開發和製作,擁有豐富資源。截至公吿日期,真相影業由樑龍飛全資持有。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.